{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:20:48Z","timestamp":1793186448253,"version":"4.5.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40263-014-0140-z","type":"journal-article","created":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T21:20:35Z","timestamp":1390252835000},"page":"147-156","source":"Crossref","is-referenced-by-count":278,"title":["Clinical Relevance of Brain Volume Measures in Multiple Sclerosis"],"prefix":"10.1007","volume":"28","author":[{"given":"Nicola","family":"De Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Airas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich P.","family":"Mattle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"O\u2019Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Walczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,22]]},"reference":[{"key":"140_CR1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221\u201331.","journal-title":"Lancet"},{"key":"140_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","volume":"93","author":"R Dutta","year":"2011","unstructured":"Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 2011;93:1\u201312.","journal-title":"Prog Neurobiol"},{"key":"140_CR3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/qjmed\/hcr012","volume":"104","author":"CA Young","year":"2011","unstructured":"Young CA. Factors predisposing to the development of multiple sclerosis. QJM. 2011;104:383\u20136.","journal-title":"QJM"},{"key":"140_CR4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.tins.2010.01.002","volume":"33","author":"V Siffrin","year":"2010","unstructured":"Siffrin V, Vogt J, Radbruch H, et al. Multiple sclerosis\u2014candidate mechanisms underlying CNS atrophy. Trends Neurosci. 2010;33:202\u201310.","journal-title":"Trends Neurosci"},{"key":"140_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2007-1019124","volume":"28","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A. The immunology of multiple sclerosis. Semin Neurol. 2008;28:29\u201345.","journal-title":"Semin Neurol"},{"key":"140_CR6","first-page":"343","volume":"4","author":"LJ Barten","year":"2010","unstructured":"Barten LJ, Allington DR, Procacci KA, et al. New approaches in the management of multiple sclerosis. Drug Des Devel Ther. 2010;4:343\u201366.","journal-title":"Drug Des Devel Ther"},{"key":"140_CR7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1474-4422(12)70003-0","volume":"11","author":"M Filippi","year":"2012","unstructured":"Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012;11:349\u201360.","journal-title":"Lancet Neurol"},{"key":"140_CR8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/1352458513482387","volume":"19","author":"M Filippi","year":"2013","unstructured":"Filippi M, Rocca M. Preventing brain atrophy should be the gold standard of effective theraphy in MS (after the first year of treatment): no. Mult Scler. 2013;19:1005\u20136.","journal-title":"Mult Scler"},{"key":"140_CR9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/1352458513482385","volume":"19","author":"RA Rudick","year":"2013","unstructured":"Rudick RA, Fisher E. Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): yes. Mult Scler. 2013;19:1003\u20134.","journal-title":"Mult Scler"},{"key":"140_CR10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/1352458513490550","volume":"19","author":"D Arnold","year":"2013","unstructured":"Arnold D, De Stefano N. Preventing brain atrophy should be the gold standard of effective therapy in multiple sclerosis (after the first year of treatment): commentary. Mult Scler. 2013;19:1007\u20138.","journal-title":"Mult Scler"},{"key":"140_CR11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrneurol.2009.41","volume":"5","author":"F Barkhof","year":"2009","unstructured":"Barkhof F, Calabresi PA, Miller DH, et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5:256\u201366.","journal-title":"Nat Rev Neurol"},{"issue":"3 Suppl.","key":"140_CR12","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1111\/j.1552-6569.2004.tb00276.x","volume":"14","author":"R Zivadinov","year":"2004","unstructured":"Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging. 2004;14(3 Suppl.):27S\u201335S.","journal-title":"J Neuroimaging"},{"key":"140_CR13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(06)70349-0","volume":"5","author":"RA Bermel","year":"2006","unstructured":"Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5:158\u201370.","journal-title":"Lancet Neurol"},{"key":"140_CR14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.nic.2008.06.007","volume":"18","author":"A Giorgio","year":"2008","unstructured":"Giorgio A, Battaglini M, Smith SM, et al. Brain atrophy assessment in multiple sclerosis: importance and limitations. Neuroimaging Clin N Am. 2008;18:675\u201386.","journal-title":"Neuroimaging Clin N Am"},{"issue":"Suppl 1","key":"140_CR15","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0022-510X(09)71297-3","volume":"287","author":"F Zipp","year":"2009","unstructured":"Zipp F. A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes. J Neurol Sci. 2009;287(Suppl 1):S24\u20139.","journal-title":"J Neurol Sci"},{"key":"140_CR16","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1212\/01.WNL.0000161871.83614.BB","volume":"64","author":"C Enzinger","year":"2005","unstructured":"Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005;64:1704\u201311.","journal-title":"Neurology"},{"key":"140_CR17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1212\/WNL.0b013e3181b2a706","volume":"73","author":"R Zivadinov","year":"2009","unstructured":"Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology. 2009;73:504\u201310.","journal-title":"Neurology"},{"key":"140_CR18","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3174\/ajnr.A3107","volume":"33","author":"F Durand-Dubief","year":"2012","unstructured":"Durand-Dubief F, Belaroussi B, Armspach JP, et al. Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. Am J Neuroradiol. 2012;33:1918\u201324.","journal-title":"Am J Neuroradiol"},{"key":"140_CR19","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.53.8.1698","volume":"53","author":"RA Rudick","year":"1999","unstructured":"Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999;53:1698\u2013704.","journal-title":"Neurology"},{"key":"140_CR20","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(04)17271-1","volume":"364","author":"M Filippi","year":"2004","unstructured":"Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:1489\u201396.","journal-title":"Lancet"},{"key":"140_CR21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(09)70237-6","volume":"8","author":"L Kappos","year":"2009","unstructured":"Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8:987\u201397.","journal-title":"Lancet Neurol"},{"issue":"Pt 11","key":"140_CR22","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/brain\/123.11.2256","volume":"123","author":"PD Molyneux","year":"2000","unstructured":"Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000;123(Pt 11):2256\u201363.","journal-title":"Brain"},{"key":"140_CR23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1212\/01.WNL.0000120663.85143.B3","volume":"62","author":"MP Sormani","year":"2004","unstructured":"Sormani MP, Rovaris M, Valsasina P, et al. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology. 2004;62:1432\u20134.","journal-title":"Neurology"},{"key":"140_CR24","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458512469695","volume":"19","author":"G Comi","year":"2013","unstructured":"Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013;19:1074\u201383.","journal-title":"Mult Scler"},{"key":"140_CR25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/1352458512473190","volume":"19","author":"A Vidal-Jordana","year":"2013","unstructured":"Vidal-Jordana A, Sastre-Garriga J, P\u00e9rez-Miralles F, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler. 2013;19:1175\u201381.","journal-title":"Mult Scler"},{"key":"140_CR26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","volume":"68","author":"DH Miller","year":"2007","unstructured":"Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390\u2013401.","journal-title":"Neurology"},{"key":"140_CR27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","volume":"74","author":"F Barkhof","year":"2010","unstructured":"Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74:1033\u201340.","journal-title":"Neurology"},{"key":"140_CR28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387\u2013401.","journal-title":"N Engl J Med"},{"key":"140_CR29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293\u2013303.","journal-title":"N Engl J Med"},{"key":"140_CR30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","volume":"366","author":"G Comi","year":"2012","unstructured":"Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000\u20139.","journal-title":"N Engl J Med"},{"key":"140_CR31","doi-asserted-by":"crossref","unstructured":"Filippi M, Rocca MA, Pagani E, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry. Epub 12 Sep 2013.","DOI":"10.1136\/jnnp-2013-306132"},{"key":"140_CR32","unstructured":"Vollmer TL, Soelberg Sorensen P, Arnold DL, et al. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing\u2013remitting multiple sclerosis. ECTRIMS 2011. Abstract P148."},{"key":"140_CR33","unstructured":"Arnold DL, Gold R, Kappos L, et al. Effects of BG-12 on magnetic resonance imaging outcomes in the DEFINE study. CMSC 2012. Poster DX21."},{"key":"140_CR34","unstructured":"Miller D, Fox RJ, Phillips JT, et al. Effects of BG-12 on magnetic resonance imaging outcomes in CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis), a randomized, placebo-controlled, phase 3 study. ENS 2012. O259."},{"key":"140_CR35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","volume":"8","author":"P O\u2019Connor","year":"2009","unstructured":"O\u2019Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20\u00a0mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889\u201397.","journal-title":"Lancet Neurol"},{"key":"140_CR36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/01.WNL.0000149516.30155.B8","volume":"64","author":"M Hardmeier","year":"2005","unstructured":"Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFN beta-1a. Neurology. 2005;64:236\u201340.","journal-title":"Neurology"},{"key":"140_CR37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.msard.2012.10.002","volume":"2","author":"IT Borges","year":"2013","unstructured":"Borges IT, Shea CD, Ohayon J, et al. The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2013;2:133\u201340.","journal-title":"Mult Scler Relat Disord"},{"key":"140_CR38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.brainres.2010.02.035","volume":"1325","author":"K Bendfeldt","year":"2010","unstructured":"Bendfeldt K, Egger H, Nichols TE, et al. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis\u2014a longitudinal MRI study. Brain Res. 2010;1325:174\u201382.","journal-title":"Brain Res"},{"key":"140_CR39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2011.08.034","volume":"312","author":"O Khan","year":"2012","unstructured":"Khan O, Bao F, Shah M, et al. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. J Neurol Sci. 2012;312:7\u201312.","journal-title":"J Neurol Sci"},{"key":"140_CR40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1468-1331.2012.03882.x","volume":"20","author":"E Portaccio","year":"2013","unstructured":"Portaccio E, Stromillo ML, Goretti B, et al. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. Eur J Neurol. 2013;20:986\u201390.","journal-title":"Eur J Neurol"},{"key":"140_CR41","doi-asserted-by":"crossref","unstructured":"CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786\u2013801.","DOI":"10.1056\/NEJMoa0802670"},{"key":"140_CR42","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829\u201339.","journal-title":"Lancet"},{"key":"140_CR43","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819\u201328.","journal-title":"Lancet"},{"key":"140_CR44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med"},{"key":"140_CR45","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.ejrad.2011.10.011","volume":"81","author":"H Takao","year":"2012","unstructured":"Takao H, Hayashi N, Ohtomo K. A longitudinal study of brain volume changes in normal aging. Eur J Radiol. 2012;81:2801\u20134.","journal-title":"Eur J Radiol"},{"key":"140_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroimage.2008.08.030","volume":"44","author":"A Sidaros","year":"2009","unstructured":"Sidaros A, Skimminge A, Liptrot MG, et al. Long-term global and regional brain volume changes following severe traumatic brain injury: a longitudinal study with clinical correlates. Neuroimage. 2009;44:1\u20138.","journal-title":"Neuroimage"},{"key":"140_CR47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archneur.60.7.989","volume":"60","author":"RI Scahill","year":"2003","unstructured":"Scahill RI, Frost C, Jenkins R, et al. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol. 2003;60:989\u201394.","journal-title":"Arch Neurol"},{"key":"140_CR48","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hbm.21334","volume":"33","author":"AM Hedman","year":"2012","unstructured":"Hedman AM, van Haren NE, Schnack HG, et al. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp. 2012;33:1987\u20132002.","journal-title":"Hum Brain Mapp"},{"key":"140_CR49","doi-asserted-by":"crossref","unstructured":"Giorgio A, Stromillo ML, Bartolozzi ML, et al. Ten-year brain atrophy and disability changes in multiple sclerosis. AAN 2012. Poster P065.","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P03.065"},{"key":"140_CR50","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/WNL.0b013e3181e24136","volume":"74","author":"N Stefano De","year":"2010","unstructured":"De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74:1868\u201376.","journal-title":"Neurology"},{"key":"140_CR51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ana.21436","volume":"64","author":"E Fisher","year":"2008","unstructured":"Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64:255\u201365.","journal-title":"Ann Neurol"},{"key":"140_CR52","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1352458506070823","volume":"12","author":"JH Simon","year":"2006","unstructured":"Simon JH. Brain atrophy in multiple sclerosis: what we know and would like to know. Mult Scler. 2006;12:679\u201387.","journal-title":"Mult Scler"},{"key":"140_CR53","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/jnnp.2007.124123","volume":"79","author":"A Minneboo","year":"2008","unstructured":"Minneboo A, Jasperse B, Barkhof F, et al. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J Neurol Neurosurg Psychiatry. 2008;79:917\u201323.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"140_CR54","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archneur.64.8.1157","volume":"64","author":"MP Amato","year":"2007","unstructured":"Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol. 2007;64:1157\u201361.","journal-title":"Arch Neurol"},{"key":"140_CR55","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/1352458509103715","volume":"15","author":"LK Fisniku","year":"2009","unstructured":"Fisniku LK, Altmann DR, Cercignani M, et al. Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler. 2009;15:668\u201377.","journal-title":"Mult Scler"},{"key":"140_CR56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1148\/radiol.11101362","volume":"259","author":"M Filippi","year":"2011","unstructured":"Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology. 2011;259:659\u201381.","journal-title":"Radiology"},{"key":"140_CR57","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1148\/radiol.13122424","volume":"268","author":"R Zivadinov","year":"2013","unstructured":"Zivadinov R, Havrdov\u00e1 E, Bergsland N, et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology. 2013;268:831\u201341.","journal-title":"Radiology"},{"key":"140_CR58","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1136\/jnnp-2012-304094","volume":"84","author":"V Popescu","year":"2013","unstructured":"Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1082\u201391.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"140_CR59","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3174\/ajnr.A3503","volume":"34","author":"R Zivadinov","year":"2013","unstructured":"Zivadinov R, Bergsland N, Dolezal O, et al. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5\u00a0years. Am J Neuroradiol. 2013;34:1931\u20139.","journal-title":"Am J Neuroradiol"},{"key":"140_CR60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.21423","volume":"64","author":"LK Fisniku","year":"2008","unstructured":"Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008;64:247\u201354.","journal-title":"Ann Neurol"},{"key":"140_CR61","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.neuroimage.2005.03.008","volume":"26","author":"MP Sanfilipo","year":"2005","unstructured":"Sanfilipo MP, Benedict RH, Sharma J, et al. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage. 2005;26:1068\u201377.","journal-title":"Neuroimage"},{"key":"140_CR62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/135245850000600602","volume":"6","author":"E Fisher","year":"2000","unstructured":"Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler. 2000;6:373\u20137.","journal-title":"Mult Scler"},{"key":"140_CR63","doi-asserted-by":"crossref","first-page":"e37049","DOI":"10.1371\/journal.pone.0037049","volume":"7","author":"N Shiee","year":"2012","unstructured":"Shiee N, Bazin PL, Zackowski KM, et al. Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One. 2012;7:e37049.","journal-title":"PLoS One"},{"key":"140_CR64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.neubiorev.2013.03.006","volume":"37","author":"J Lansley","year":"2013","unstructured":"Lansley J, Mataix-Cols D, Grau M, et al. Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. Neurosci Biobehav Rev. 2013;37:819\u201330.","journal-title":"Neurosci Biobehav Rev"},{"key":"140_CR65","first-page":"231345","volume":"2013","author":"R Zivadinov","year":"2013","unstructured":"Zivadinov R, Tekwe C, Bergsland N, et al. Bimonthly evolution of cortical atrophy in early relapsing\u2013remitting multiple sclerosis over 2 years: a longitudinal study. Mult Scler Int. 2013;2013:231345.","journal-title":"Mult Scler Int"},{"key":"140_CR66","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1212\/01.WNL.0000036271.49066.06","volume":"59","author":"E Fisher","year":"2002","unstructured":"Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59:1412\u201320.","journal-title":"Neurology"},{"key":"140_CR67","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1212\/WNL.54.8.1689","volume":"54","author":"PA Brex","year":"2000","unstructured":"Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology. 2000;54:1689\u201391.","journal-title":"Neurology"},{"key":"140_CR68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp.73.2.141","volume":"73","author":"CM Dalton","year":"2002","unstructured":"Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;73:141\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"140_CR69","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1177\/1352458513488231","volume":"19","author":"F P\u00e9rez-Miralles","year":"2013","unstructured":"P\u00e9rez-Miralles F, Sastre-Garriga J, Tintor\u00e9 M, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler. 2013;19:1878\u201386.","journal-title":"Mult Scler"},{"key":"140_CR70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1191\/1352458502ms778oa","volume":"8","author":"GT Ingle","year":"2002","unstructured":"Ingle GT, Stevenson VL, Miller DH, et al. Two-year follow-up study of primary and transitional progressive multiple sclerosis. Mult Scler. 2002;8:108\u201314.","journal-title":"Mult Scler"},{"key":"140_CR71","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/135245850000600601","volume":"6","author":"RA Rudick","year":"2000","unstructured":"Rudick RA, Fisher E, Lee JC, et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler. 2000;6:365\u201372.","journal-title":"Mult Scler"},{"key":"140_CR72","doi-asserted-by":"crossref","unstructured":"Lavorgna L, Bonavita S, Ippolito D, et al. Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Mult Scler. Epub 9 Jul 2013.","DOI":"10.1177\/1352458513494958"},{"key":"140_CR73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458513492245","volume":"20","author":"H Kearney","year":"2014","unstructured":"Kearney H, Rocca M, Valsasina P, et al. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler. 2014;20:72\u201380.","journal-title":"Mult Scler"},{"key":"140_CR74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp-2012-303821","volume":"84","author":"MA Rocca","year":"2013","unstructured":"Rocca MA, Valsasina P, Damjanovic D, et al. Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes. J Neurol Neurosurg Psychiatry. 2013;84:35\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"140_CR75","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1148\/radiol.13122566","volume":"269","author":"C Lukas","year":"2013","unstructured":"Lukas C, Sombekke MH, Bellenberg B, et al. Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology. 2013;269:542\u201352.","journal-title":"Radiology"},{"key":"140_CR76","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1148\/radiol.12120813","volume":"266","author":"P Valsasina","year":"2013","unstructured":"Valsasina P, Rocca MA, Horsfield MA, et al. Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis. Radiology. 2013;266:853\u201361.","journal-title":"Radiology"},{"key":"140_CR77","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/jnnp.2009.199968","volume":"81","author":"C Lukas","year":"2010","unstructured":"Lukas C, Minneboo A, de Groot V, et al. Early central atrophy rate predicts 5\u00a0year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1351\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"140_CR78","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2008.12.005","volume":"282","author":"D Horakova","year":"2009","unstructured":"Horakova D, Dwyer MG, Havrdova E, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci. 2009;282:112\u20139.","journal-title":"J Neurol Sci"},{"key":"140_CR79","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1148\/radiol.10100326","volume":"257","author":"MA Rocca","year":"2010","unstructured":"Rocca MA, Mesaros S, Pagani E, et al. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology. 2010;257:463\u20139.","journal-title":"Radiology"},{"key":"140_CR80","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.wnl.0000435551.90824.d0","volume":"81","author":"M Filippi","year":"2013","unstructured":"Filippi M, Preziosa P, Copetti M, et al. Gray matter damage predicts the accumulation of disability 13\u00a0years later in MS. Neurology. 2013;81:1759\u201367.","journal-title":"Neurology"},{"key":"140_CR81","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/13803395.2011.614597","volume":"33","author":"TJ Covey","year":"2011","unstructured":"Covey TJ, Zivadinov R, Shucard JL, et al. Information processing speed, neural efficiency, and working memory performance in multiple sclerosis: differential relationships with structural magnetic resonance imaging. J Clin Exp Neuropsychol. 2011;33:1129\u201345.","journal-title":"J Clin Exp Neuropsychol"},{"key":"140_CR82","doi-asserted-by":"crossref","unstructured":"Nocentini U, Bozzali M, Span\u00f3 B, et al. Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis. Brain Imaging Behav. Epub 15 May 2012.","DOI":"10.1007\/s11682-012-9170-7"},{"key":"140_CR83","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1177\/1352458513478675","volume":"19","author":"RH Benedict","year":"2013","unstructured":"Benedict RH, Hulst HE, Bergsland N, et al. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Mult Scler. 2013;19:1478\u201384.","journal-title":"Mult Scler"},{"key":"140_CR84","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.0b013e318212a8be","volume":"76","author":"MS Deloire","year":"2011","unstructured":"Deloire MS, Ruet A, Hamel D, et al. MRI predictors of cognitive outcome in early multiple sclerosis. Neurology. 2011;76:1161\u20137.","journal-title":"Neurology"},{"key":"140_CR85","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1586\/ern.10.155","volume":"11","author":"M Calabrese","year":"2011","unstructured":"Calabrese M, Rinaldi F, Grossi P, et al. Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev Neurother. 2011;11:425\u201332.","journal-title":"Expert Rev Neurother"},{"key":"140_CR86","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/brain\/awn030","volume":"131","author":"NL Sicotte","year":"2008","unstructured":"Sicotte NL, Kern KC, Giesser BS, et al. Regional hippocampal atrophy in multiple sclerosis. Brain. 2008;131:1134\u201341.","journal-title":"Brain"},{"key":"140_CR87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1212\/01.WNL.0000129544.79539.D5","volume":"63","author":"MP Amato","year":"2004","unstructured":"Amato MP, Bartolozzi ML, Zipoli V, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology. 2004;63:89\u201393.","journal-title":"Neurology"},{"key":"140_CR88","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1212\/WNL.0b013e31828726cc","volume":"80","author":"HE Hulst","year":"2013","unstructured":"Hulst HE, Steenwijk MD, Versteeg A, et al. Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. Neurology. 2013;80:1025\u201332.","journal-title":"Neurology"},{"key":"140_CR89","doi-asserted-by":"crossref","first-page":"e44826","DOI":"10.1371\/journal.pone.0044826","volume":"7","author":"F Rossi","year":"2012","unstructured":"Rossi F, Giorgio A, Battaglini M, et al. Relevance of brain lesion location to cognition in relapsing multiple sclerosis. PLoS One. 2012;7:e44826.","journal-title":"PLoS One"},{"key":"140_CR90","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1474-4422(10)70131-9","volume":"9","author":"R Kapoor","year":"2010","unstructured":"Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9:681\u20138.","journal-title":"Lancet Neurol"},{"key":"140_CR91","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.wnl.0000316810.01120.05","volume":"71","author":"R Zivadinov","year":"2008","unstructured":"Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008;71:136\u201344.","journal-title":"Neurology"},{"key":"140_CR92","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/archneurol.2008.567","volume":"66","author":"SA Gauthier","year":"2009","unstructured":"Gauthier SA, Berger AM, Liptak Z, et al. Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009;66:234\u20137.","journal-title":"Arch Neurol"},{"key":"140_CR93","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.neurobiolaging.2008.11.004","volume":"31","author":"JR Romero","year":"2010","unstructured":"Romero JR, Vasan RS, Beiser AS, et al. Association of matrix metalloproteinases with MRI indices of brain ischemia and aging. Neurobiol Aging. 2010;31:2128\u201335.","journal-title":"Neurobiol Aging"},{"key":"140_CR94","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458509102920","volume":"15","author":"F Bernal","year":"2009","unstructured":"Bernal F, Elias B, Hartung HP, et al. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult Scler. 2009;15:721\u20137.","journal-title":"Mult Scler"},{"key":"140_CR95","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1212\/WNL.0b013e318227b227","volume":"77","author":"S Debette","year":"2011","unstructured":"Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77:461\u20138.","journal-title":"Neurology"},{"key":"140_CR96","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1212\/WNL.0b013e318296e98b","volume":"80","author":"JF Sumowski","year":"2013","unstructured":"Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve and cognitive reserve in multiple sclerosis: what you\u2019ve got and how you use it. Neurology. 2013;80:2186\u201393.","journal-title":"Neurology"},{"key":"140_CR97","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1212\/WNL.0b013e3182918c6f","volume":"80","author":"MP Amato","year":"2013","unstructured":"Amato MP, Razzolini L, Goretti B, et al. Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. Neurology. 2013;80:1728\u201333.","journal-title":"Neurology"},{"key":"140_CR98","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00415-013-6952-9","volume":"260","author":"A Feinstein","year":"2013","unstructured":"Feinstein A, Lapshin H, O\u2019Connor P, et al. Sub-threshold cognitive impairment in multiple sclerosis: the association with cognitive reserve. J Neurol. 2013;260:2256\u201361.","journal-title":"J Neurol"},{"key":"140_CR99","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1017\/S1355617713001082","volume":"19","author":"AJ Booth","year":"2013","unstructured":"Booth AJ, Rodgers JD, Schwartz CE, et al. Active cognitive reserve influences the regional atrophy to cognition link in multiple sclerosis. J Int Neuropsychol Soc. 2013;19:1128\u201333.","journal-title":"J Int Neuropsychol Soc"},{"key":"140_CR100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jns.2005.03.006","volume":"233","author":"R Zivadinov","year":"2005","unstructured":"Zivadinov R. Steroids and brain atrophy in multiple sclerosis. J Neurol Sci. 2005;233:73\u201381.","journal-title":"J Neurol Sci"},{"key":"140_CR101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2011.190","volume":"8","author":"F Barkhof","year":"2011","unstructured":"Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol. 2011;8:13\u201321.","journal-title":"Nat Rev Neurol"},{"key":"140_CR102","doi-asserted-by":"crossref","unstructured":"Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. Epub 5 Sep 2013.","DOI":"10.1002\/ana.24018"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0140-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0140-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0140-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T19:01:01Z","timestamp":1688929261000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0140-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0140-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,22]]}}}